In December of 2025, the FDA approved a once-daily pill version of Wegovy
This team might include a doctor, diabetes educator, lactation consultant, and dietitian
A race to affordability in obesity care Increased access for patients in emerging markets Pressure on global leaders like Novo Nordisk A shift from innovation monopoly competitive ecosystem The real question is: Will lower pricing accelerate adoption, or squeeze long-term innovation
and change from baseline to week 104 in pulse, amylase, lipase and calcitonin
Thigh vs abdomen vs upper arm: which site is best
Coverage gaps also emerge when switching doses or adjusting treatment frequency, as many BCBS plans limit quantity dispensed per fill or restrict refill timing